Images List Premium Download Classic

Liver Disease

Liver Disease-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Methods and compositions for the treatment of non-alcoholic steatohepatitis
Vivus, Inc.
November 09, 2017 - N°20170319540

The present disclosure relates to methods of preventing, treating, delaying the onset of, and delaying the progression of liver disease by administering topiramate in combination with phentermine to a patient in need thereof.
Compositions and methods for lipid metabolism disorder
Vivus, Inc.
November 02, 2017 - N°20170312286

A method for inhibiting a lipid metabolism disorder of a warm-blooded animal includes administering a therapeutically effective amount of a compound being one selected from the group consisting of phosphodiesterase 5 (pde-5) inhibitors of the first type and second type and a statin analogue to a warm-blooded animal suffering from the lipid metabolism disorder. The method may treat the disease selected ...
Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products
The Regents Of The University Of California
October 26, 2017 - N°20170304233

The disclosure relates, in general, to treatment of fatty liver disorders comprising administering compositions comprising cysteamine products. The disclosure provides administration of enterically coated cysteamine compositions to treat fatty liver disorders, such as non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash).
Liver Disease Patent Pack
Download 100+ patent application PDFs
Liver Disease Patent Applications
Download 100+ Liver Disease-related PDFs
For professional research & prior art discovery
inventor
  • 100+ full patent PDF documents of Liver Disease-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Use of a long acting glp-1/glucagon receptor dual agonist for the treatment of non-alcoholic ...
Golden Biotechnology Corporation
October 19, 2017 - N°20170298117

The present invention relates to a pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease including a long-acting glp-1/glucagon receptor dual agonist, and a method for preventing or treatment of non-alcoholic fatty liver disease including administering the composition. The composition of the present invention either has no side effect of weight gain or reduces the side ...
Methods of lowering serum cholesterol
Golden Biotechnology Corporation
October 19, 2017 - N°20170296653

Methods of treating subjects having diseases, disorders, or conditions, including disorders associated with cholesterol homeostasis, responsive to agents modulating kupffer cell function, including methods of administration and dosing regimens associated therewith, are provided. Methods of treating subjects having liver diseases, disorders, or conditions, including non-alcoholic steatohepatitis and non-alcoholic fatty liver disease, with an il-10 agent are also provided.
Composition including extract of dolichos lablab linne as active ingredient for preventing or ameliorating non-alcoholic ...
Golden Biotechnology Corporation
October 19, 2017 - N°20170296607

A health functional food composition and a pharmaceutical composition for preventing or ameliorating a non-alcoholic fatty liver disease include an extract of dolichos lablab linne as an active ingredient. The extract of dolichos lablab linne, being an active ingredient, effectively reduces accumulation of triglyceride in hepatocarcinoma cell line (hepg2). Therefore, the compositions are used for functional foods and medicines for ...
Liver Disease Patent Pack
Download 100+ patent application PDFs
Liver Disease Patent Applications
Download 100+ Liver Disease-related PDFs
For professional research & prior art discovery
inventor
  • 100+ full patent PDF documents of Liver Disease-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Oral adsorbent and method for producing oral adsorbent
Power Japan Plus Inc.
October 12, 2017 - N°20170290856

Activated carbon (for example medicinal carbon), which has long been used for adsorbing and removing harmful substances from the digestive system, has the drawback of causing constipation, and the production of a spherical adsorbent carbon that is believed to overcome this drawback from a petroleum-based hydrocarbon requires a complicated production process. These issues can be addressed by an oral adsorbent, ...
Alpha-1 anti-trypsin for treating liver diseases
Hadasit Medical Research Services And Development Ltd.
October 05, 2017 - N°20170281739

Methods of treating liver diseases are provided. Accordingly there is provided a method of treating a liver disease selected from the group consisting of fatty liver disease and chronic liver rejection in a subject in need thereof, wherein said liver disease is not associated with genetic alpha-1 anti-trypsin (aat) deficiency, the method comprising administering to the subject a therapeutically effective ...
Methods of treating fatty liver disease
Genzyme Corporation
October 05, 2017 - N°20170281593

The disclosure provides methods for treating fatty liver disease and associated conditions by inhibiting the synthesis of glucosphingolipids, as exemplified by the use of glucosylceramide synthase substrate analogs.
Methods of treating liver disease
Gilead Sciences, Inc.
September 28, 2017 - N°20170273952

The present disclosure relates to a method of preventing and/or treating liver disease comprising administering an ask1 inhibitor in combination with a fxr agonist, to a patient in need thereof.
Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of ...
Sancilio & Company, Inc.
September 14, 2017 - N°20170258752

Described herein are compositions including at least one omega-3 fatty acid (either in the triglyceride, ester or free fatty acid ester form) and at least one surface active agent; wherein the compositions form micelles when in contact with an aqueous medium. Also provided are methods of administering to a subject a composition including at least one omega-3 fatty acid (either ...
Fatty acid cysteamine conjugates and their use as activators of autophagy
Catabasis Pharmaceuticals, Inc.
September 14, 2017 - N°20170258741

The invention relates to (i) 6-membered heteroaryl substituted fatty acid cystamine conjugates, compositions thereof, methods of treating diseases involving dysregulation of autophagy, such as cystic fibrosis, idiopathic pulmonary fibrosis (ipf), a neurodegenerative disease, inflammatory disease, liver disease, muscle disease, infection and immune disease with this compound, or (ii) a method of treating idiopathic pulmonary fibrosis, mitochondrial diseases, leigh syndrome, diabetes ...
Method for preventing, improving or treating liver disease
Wonkwang University Center For Industry-academy Cooperation
September 07, 2017 - N°20170252395

The present invention provides a method for preventing, alleviating or treating a liver disease, comprising administering a composition comprising a triticum aestivum lamarck leaf extract or a fraction thereof to a subject in need thereof. Therefore, the method for preventing, alleviating or treating a liver disease of the present invention can improve the morphological change of liver tissue due to ...
Liver Disease Patent Pack
Download 100+ patent application PDFs
Liver Disease Patent Applications
Download 100+ Liver Disease-related PDFs
For professional research & prior art discovery
inventor
  • 100+ full patent PDF documents of Liver Disease-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Adsorbent for oral administration, agent for treating renal disease, and agent for treating liver disease
Chr. Hansen A/s
September 07, 2017 - N°20170252370

The above problem can be solved by an adsorbent for oral administration comprising a spherical activated carbon, the activated carbon having a specific surface area determined by the bet method of 800 m2/g or more, a bulk density of from 0. 3 g/ml to 0. 8 g/ml, a volume of pores having a diameter less than 3 nm of 0. 3 ml/g or more, ...
Method for producing adult liver progenitor cells
Promethera Biosciences S.a./n.v.
August 24, 2017 - N°20170240863

Novel adult liver progenitor cells (called h2stem cells) have been have been characterized on the basis of a series of biological activities and markers. Methods for producing h2stem cells allow providing such cells in the form of adherent cells and three-dimensional cell clusters in suspension that can be differentiated into cells having strong liver-specific activities and/or that ...
Compositions and methods to relieve chronic diseases symptoms
Hxls Charity Corp.
August 24, 2017 - N°20170239305

Compounds having unique properties are prepared from the herbal compositions described herein and comprise extracts derived from plants and fungi of the genera panax, ganoderma, and saussurea. The compositions are useful in preventing, treating, relieving, and improving the quality-of-life of patients suffering from chronic diseases, such as liver diseases, cancer, cachexia, and immune system disorders.
Cenicriviroc for the treatment of fibrosis
Tobira Therapeutics ,inc.
August 24, 2017 - N°20170239262

The present disclosure provides methods of treating fibrosis or a fibrotic disease or condition in a subject in need thereof comprising administering to the subject a therapeutically effective amount of cenicriviroc or a salt or solvate thereof. The fibrosis or fibrotic disease may be liver fibrosis, renal fibrosis, non-cirrhotic hepatic fibrosis, associated with non-alcoholic steatohepatitis (nash), non-alcoholic fatty liver disease (...
(aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use
Bayer Pharma Aktiengesellschaft
August 24, 2017 - N°20170239251

The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein ...
Novel compositions and methods useful for treating or preventing liver diseases or disorders, and promoting ...
Yale University
August 17, 2017 - N°20170232027

The invention includes a method of preventing or treating a toxic liver disease or disorder, such as but not limited to non-alcoholic steatohepatitis (nash), liver injury associated with or caused by alcohol consumption in a mammal afflicted with nash, alcoholic hepatitis, drug induced liver injury, primary sclerosing cholangitis, viral hepatitis, liver fibrosis, liver cirrhosis, and other toxic liver conditions, in ...
Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
Somalogic, Inc.
August 10, 2017 - N°20170227550

Methods, compositions, and kits for determining whether a subject has non-alcoholic fatty liver disease (nafld) are provided. Methods, compositions, and kits for determining whether a subject has non-alcoholic steatosis are also provided. Methods, compositions, and kits for determining whether a subject has non-alcoholic steatohepatitis (nash) are also provided.
Preparation and uses of obeticholic acid
Somalogic, Inc.
August 10, 2017 - N°20170226149

Or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof. Obeticholic acid is useful for the treatment or prevention of a fxr mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing hdl cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis. The present invention also relates to processes for the synthesis of ...
Loading